# Fruquintinib Plus Anti-EGFR Antibody for Third-Line Treatment of RAS Wild-Type mCRC

> **NCT07724223** · PHASE2 · RECRUITING · sponsor: **Cancer Institute and Hospital, Chinese Academy of Medical Sciences** · enrollment: 46 (estimated)

## Conditions studied

- Metastatic Colorectal Cancer (CRC)

## Interventions

- **DRUG:** Fruquintinib plus Cetuximab-beta

## Key facts

- **NCT ID:** NCT07724223
- **Lead sponsor:** Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-01-16
- **Primary completion:** 2028-10-01
- **Final completion:** 2029-01-31
- **Target enrollment:** 46 (ESTIMATED)
- **Last updated:** 2026-07-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07724223

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07724223, "Fruquintinib Plus Anti-EGFR Antibody for Third-Line Treatment of RAS Wild-Type mCRC". Retrieved via MORVS 2026-10-21 from https://api.morvs.ai/clinical/NCT07724223. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*